ABCL

AbCellera Biologics Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Shareholders held by AbCellera Biologics Inc. on June 12, 2025. The record date for the meeting was April 15, 2025, with 298,423,569 common shares outstanding and entitled to vote.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.

Material Changes and Voting Results

Shareholders voted on three proposals, all of which were approved:

• Proposal 1 (Director Election): Carl L. G. Hansen, Ph.D., and Michael Hayden, MBCHB (M.D.), Ph.D., were elected as Class II directors for a three-year term.
• Proposal 2 (Auditor Ratification): KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Proposal 3 (Say-on-Pay): Shareholders approved the compensation of named executive officers on a non-binding advisory basis.

Voting Breakdown

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document is limited to the disclosure of voting results.

Key Facts for Investor Verification

• Verify the tenure and qualifications of the newly elected Class II directors, Carl L. G. Hansen and Michael Hayden.
• Note the significant number of abstentions for Michael Hayden (26.8 million shares) compared to Carl Hansen (6.8 million shares).
• Confirm the total broker non-votes, which exceeded 33 million shares for director elections and 35 million for the Say-on-Pay proposal.
• Review the Definitive Proxy Statement filed on April 29, 2025, for detailed background on the proposals.